微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 39.59% | 7.94% | 0% | 95/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 39.59% | 6.61% | -2.44% | 93/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 40.58% | -0.39% | 9.77% | 93/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 36.97% | -30.2% | 0.79% | 101/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 36.68% | -30.75% | -1.24% | 99/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 37.14% | -30.41% | -8.84% | 100/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 40.74% | -20.17% | -23.07% | 91/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 52.96% | -0.76% | -0.01% | 74/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 52.96% | -4.9% | -0.75% | 72/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 53.37% | -5.91% | 4.58% | 73/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 51.03% | -12.3% | -4.38% | 75/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 53.36% | -8.57% | -4.18% | 70/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 55.69% | -6.81% | -1.81% | 67/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 56.72% | -5.53% | -2.51% | 64/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 58.18% | -4.46% | -0.32% | 58/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.37% | -7.12% | -2.33% | 61/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 59.76% | -8% | -0.48% | 54/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 60.05% | -6.27% | -1.41% | 57/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.9% | -3.19% | -3.09% | 55/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 62.85% | -3.9% | -3.25% | 57/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.96% | 0.68% | 1.39% | 43/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 64.06% | 0.72% | 1.84% | 49/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 62.91% | -2.3% | -3.81% | 43/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 65.4% | 2.6% | 1.36% | 48/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 64.52% | -0.77% | 1.43% | 42/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 63.61% | -2.86% | -1.21% | 45/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 64.39% | 0.53% | 1.02% | 38/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 63.74% | 3.34% | -1.97% | 48/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 65.02% | 3.91% | -0.71% | 33/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 65.48% | 3.77% | 2.24% | 36/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 64.04% | -0.39% | 3.84% | 33/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 61.67% | 9.34% | -1.43% | 48/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 62.57% | 15.76% | -0.84% | 36/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 63.1% | 25.58% | -1.86% | 34/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 64.29% | 37.85% | 13.98% | 33/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 56.41% | 20.22% | 4.36% | 52/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 54.05% | 14.46% | 7.58% | 41/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 50.24% | 5.33% | 7.72% | 44/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 46.64% | 2.2% | -0.6% | 42/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 46.92% | 6.16% | -0.63% | 54/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 47.22% | 11.69% | -1.01% | 35/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 47.7% | 25.37% | 4.53% | 39/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 45.64% | 61.78% | 3.25% | 32/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |